ReviewScientifica2016
Mycoplasma genitalium: An Emerging Sexually Transmitted Infection.
Review in Scientifica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Epidemiology of genital infections caused by Mycoplasma hominis, M. genitalium and Ureaplasma urealyticum in Iran; a systematic review and meta-analysis study (2000-2019).BMC public health · 2020Pooled it
- Article
- Prevalence and macrolide resistance of Mycoplasma genitalium from patients seeking sexual health care in Southern Ghana.BMC infectious diseases · 2024Article
- Computational approach for identifying immunogenic epitopes and optimizing peptide vaccine throughHeliyon · 2024Article
- 2023 Korean sexually transmitted infections treatment guidelines forInvestigative and clinical urology · 2024Review
- The prevalence of Mycoplasma hominis in Outpatients at a Tertiary Care Hospital in East India.Cureus · 2022Article
- Vaccinomics-Aided Development of a Next-Generation Chimeric Vaccine against an Emerging Threat:Vaccines · 2022Article
- Laboratory Diagnosis of Sexually Transmitted Infections in Cases of Suspected Child Sexual Abuse.Journal of clinical microbiology · 2020Review
- The Prevalence of Mycoplasma genitalium and Association With Human Immunodeficiency Virus Infection in Symptomatic Patients, Johannesburg, South Africa, 2007-2014.Sexually transmitted diseases · 2019Article
- Emerging and re-emerging sexually transmitted diseases: A review of epidemiological evidences.Indian journal of sexually transmitted diseases and AIDSReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma genitalium has been recognized as a cause of male urethritis, and there is now evidence suggesting that it causes cervicitis and pelvic inflammatory disease in women. M. genitalium is a slow growing organism, and, with the advent of nucleic acid amplification test (NAAT), more studies are being performed, and knowledge about the pathogenicity of this organism elucidated. With NAAT detection, treatment modalities have been studied, and the next challenge is to determine the most effective antimicrobial therapy. Doxycycline, the first-line antibiotic for urethritis, is largely ineffective in the treatment of M. genitalium and furthermore, resistance to macrolide has also emerged. The most effective drug is Moxifloxacin although there are emerging reports of resistance to it in various parts of the world. This paper not only highlights the current research and knowledge, but also reviews the diversity of health implications on the health of men and women infected with M. genitalium. Alternate antibiotics and the impact of M. genitalium on infertility are areas that require more studies as we continue to research into this microorganism.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.